SOGROYA 10mg / 1.5ml solution for injection in pre-filled pen medication leaflet

Sogroya 5 mg/1.5 mL solution for injection in pre-filled pen

Sogroya 10 mg/1.5 mL solution for injection in pre-filled pen

Sogroya 15 mg/1.5 mL solution for injection in pre-filled pen

Sogroya 5 mg/1.5 mL solution for injection in pre-filled pen

One mL of solution cotains 3.3 mg of somapacitan*

Each pre-filled pen contains 5 mg of somapacitan in 1.5 mL solution

Sogroya 10 mg/1.5 mL solution for injection in pre-filled pen

One mL of solution contains 6.7 mg of somapacitan*

Each pre-filled pen contains 10 mg of somapacitan in 1.5 mL solution

Sogroya 15 mg/1.5 mL solution for injection in pre-filled pen

One mL of solution contains 10 mg of somapacitan*

Each pre-filled pen contains 15 mg of somapacitan in 1.5 mL solution

*Produced by recombinant DNA technology in Escherichia coli followed by attachment of an albuminbinding moiety.

For the full list of excipients, see section 6.1.

Solution for injection (injection).

Clear to slightly opalescent, colourless to slightly yellow liquid and free from visible particles.

Sogroya is indicated for the replacement of endogenous growth hormone (GH) in children aged3 years and above, and adolescents with growth failure due to growth hormone deficiency (paediatric

GHD), and in adults with growth hormone deficiency (adult GHD).

Somapacitan should be initiated and monitored by physicians who are appropriately qualified andexperienced in the diagnosis and management of patients with growth hormone deficiency (e.g.endocrinologists).

Table 1: Dose recommendation

Paediatric GHD Recommended starting dose

Treatment-naïve paediatric patients and paediatric 0.16 mg/kg/weekpatients switching from other GH medicinalproducts

Adult GHD Recommended starting dose

Naïve patients

Adults (≥18 to <60 years) 1.5 mg/week

Women on oral oestrogen therapy (irrespective of 2 mg/weekage)

Elderly (60 years or older) 1 mg/week

Patients switching from daily GH medicinalproducts

Adults (≥18 to <60 years) 2 mg/week

Women on oral oestrogen therapy (irrespective of 4 mg/weekage)

Elderly (60 years or older) 1.5 mg/week

Paediatric GHD

Dose titration

Somapacitan dose may be individualised and adjusted based on growth velocity, adverse reactions,body weight and serum insulin-like growth factor I (IGF-I) concentrations.

Average IGF-I standard deviation score (SDS) levels (drawn 4 days after dosing) can guide dosetitration. Dose adjustments should be targeted to achieve average IGF-I SDS levels in the normalrange, i.e. between -2 and +2 (preferably close to 0 SDS).

If the IGF-I (SDS) is > 2, it should be reassessed after a subsequent somapacitan administration. If thevalue remains > 2, reducing the dose by 0.04 mg/kg/week is recommended. More than one dosereduction may be required in some patients.

In patients who have had the dose reduced but are not growing well, the dose may be graduallyincreased as tolerated up to a maximum dose of 0.16 mg/kg/week. Dose increments should not exceed0.02 mg/kg per week.

Treatment evaluation

Evaluation of efficacy and safety should be considered at approximately 6- to 12-month intervals andmay be assessed by evaluating auxological parameters, biochemistry (IGF-I, hormones, glucose, andlipid levels) and pubertal status. More frequent evaluations should be considered during puberty.

Treatment should be discontinued in patients having achieved final height or near final height, i.e. anannualised height velocity < 2 cm/year and a bone age > 14 years in girls or > 16 years in boys whichcorresponds to the closure of the epiphyseal growth plates, see section 4.3. Once the epiphyses arefused, patients should be clinically re-evaluated for the need for growth hormone treatment.

When GHD persists after growth completion, growth hormone treatment should be continued toachieve full somatic adult development including lean body mass and bone mineral accrual (forguidance on dosing see recommended dose for adults (Table 1)).

Adult GHD

Dose titration

The somapacitan dose must be individually adjusted for each patient. It is recommended to increasethe dose gradually with 2-4 weeks intervals in steps from 0.5 mg to 1.5 mg based on the patients’clinical response and experience of adverse reactions up to a dose of 8 mg somapacitan per week.

Serum insulin like growth factor-I (IGF-I) levels (drawn 3-4 days after dosing) can be used asguidance for the dose titration. The IGF-I standard deviation score (SDS) target should aim for theupper normal range not exceeding 2 SDS. IGF-I SDS levels in the target range are usually achievedwithin 8 weeks of dose titration. Longer dose titration may be necessary in some adult GHD patients(see below and section 5.1).

Treatment evaluation

Using IGF-I SDS as a biomarker for dose titration, the aim is to reach IGF-I SDS levels within theage-adjusted upper reference range (IGF-I SDS upper reference range: 0 and +2) within 12 months oftitration. If this target range cannot be achieved within this period, or the patient does not obtain thedesired clinical response, other treatment options should be considered.

During somapacitan maintenance treatment, evaluation of efficacy and safety should be considered atapproximately 6- to 12-month intervals and may be assessed by evaluating biochemistry (IGF-I-,glucose-, and lipid levels), body composition, and body mass index.

Paediatric and adult GHD

Switching from other growth hormone products

Patients switching from a weekly growth hormone to somapacitan are recommended to continueadministration at their once weekly dosing day.

Patients switching from daily human growth hormone to once-weekly somapacitan should choose thepreferred day for the weekly dose and inject the final dose of daily treatment the day before (or at least8 hours before) injecting the first dose of once-weekly somapacitan. Patients should follow theinstructions for the dose presented in Table 1.

Oral oestrogen therapy

Females on oral oestrogen-containing therapy may have reduced IGF-I levels and may require doseadjustment of growth hormone to achieve the treatment goal (see section 4.4).

In paediatric GHD doses above 0.16 mg/kg/week have not been studied and are not recommended.

Patients who miss a dose are advised to inject once-weekly somapacitan upon discovery as soon aspossible, within 3 days after the missed dose, and then resume their usual once-weekly dosingschedule. If more than 3 days have passed, the dose should be skipped and the next dose should beadministered on the regularly scheduled day. If two or more doses have been missed, the dose shouldbe resumed on the regularly scheduled day.

The day of weekly injection can be changed as long as the time between two doses is at least 4 days.

After selecting a new dosing day, the once weekly dosing should be continued.

Flexibility in dosing time

On occasions when injection at the scheduled dosing day is not possible, once-weekly somapacitancan be administered up to 2 days before or 3 days after the scheduled weekly dosing day as long as thetime between two doses is at least 4 days (96 hours). Once-weekly dosing for the next dose could beresumed at the regularly scheduled dosing day.

Elderly (60 years or older)

Generally, lower doses of somapacitan may be necessary in older patients. For further information, seesection 5.2.

Limited data on the clinical effects of somapacitan are available in paediatric GHD patients under3 years of age. Currently available data are described in sections 5.1 and 5.2, but no recommendationon a posology can be made.

Men show an increasing IGF-I sensitivity over time. This means that there is a risk that men areovertreated. Women, especially those on oral oestrogen, may require higher doses and a longertitration period than men, see sections 5.1 and 5.2. In females using oral oestrogen, it should beconsidered to change the route of oestrogen administration (e.g. transdermal, vaginal) see section 4.4.

No adjustment of the starting dose is required for patients with renal impairment. Patients with renalimpairment may need lower doses of somapacitan, but since the dose of somapacitan is individuallyadjusted according to the need of each patient, no further dose adjustment is required, see section 5.2.

No adjustment of the starting dose is required for patients with hepatic impairment. Patients withmoderate hepatic impairment may need higher doses of somapacitan, but since the dose ofsomapacitan is individually adjusted according to the need of each patient, no further dose adjustmentis required. No information regarding the use of somapacitan in patients with severe hepaticimpairment is available. Caution should be exercised if treating these patients with somapacitan, seesection 5.2.

Somapacitan is to be administered once-weekly at any time of the day.

Somapacitan is to be injected subcutaneously in the abdomen, thighs, buttocks or upper arms withoutdose adjustment.

The injection site should be rotated every week to prevent local lipoatrophy.

Sogroya 5 mg/1.5 mL solution for injection in pre-filled pen

The Sogroya 5 mg/1.5 mL (3.3 mg/mL) pen delivers doses from 0.025 mg (0.0075 mL) to 2 mg(0.6 mL) in increments of 0.025 mg.

Sogroya 10 mg/1.5 mL solution for injection in pre-filled pen

The Sogroya 10 mg/1.5 mL (6.7 mg/mL) pen delivers doses from 0.05 mg (0.0075 mL) to 4 mg(0.6 mL) in increments of 0.05 mg.

Sogroya 15 mg/1.5 mL solution for injection in pre-filled pen

The Sogroya 15 mg/1.5 mL (10 mg/mL) pen delivers doses from 0.10 mg (0.01 mL) to 8 mg (0.8 mL)in increments of 0.10 mg.

For instructions of the medicinal product before administration, see section 6.6.

Hypersensitivity to the active substance or to any of the excipients listed in section 6.1.

Somapacitan must not be used when there is any evidence of activity of a tumour. Intracranial tumoursmust be inactive and antitumour therapy must be completed prior to starting somapacitan therapy.

Treatment should be discontinued if there is evidence of tumour growth, see section 4.4.

Somapacitan must not be used for longitudinal growth promotion in children with closed epiphyses,see section 4.2.

Patients with acute critical illness suffering from complications following open heart surgery,abdominal surgery, multiple accidental trauma, acute respiratory failure or similar conditions must notbe treated with somapacitan (regarding patients undergoing substitution therapy, see section 4.4).

In order to improve the traceability of biological medicinal products, the name and the batch numberof the administered product should be clearly recorded.

Adrenocortical insufficiency

Introduction of growth hormone treatment may result in inhibition of 11βHSD-1 and reduced serumcortisol concentrations. In patients treated with growth hormone, previously undiagnosed central(secondary) hypoadrenalism may be unmasked and glucocorticoid replacement may be required. Inaddition, patients treated with glucocorticoid replacement for previously diagnosed hypoadrenalismmay require an increase in their maintenance or stress doses following initiation of growth hormonetreatment. It is necessary to monitor patients with known hypoadrenalism for reduced serum cortisollevels and/or for the need of increased doses of glucocorticoid, see section 4.5.

Glucose metabolism impairment

Treatment with growth hormone may decrease insulin sensitivity, particularly at higher doses insusceptible patients and consequently hyperglycaemia may occur in subjects with inadequate insulinsecretory capacity. As a result, previously undiagnosed impaired glucose tolerance and overt diabetesmellitus may be unmasked during growth hormone treatment. Therefore, glucose levels should bemonitored periodically in all patients treated with growth hormone, especially in those with riskfactors for diabetes mellitus, such as obesity, or a family history of diabetes mellitus. Patients withpre-existing type 1 or type 2 diabetes mellitus or impaired glucose tolerance should be monitoredclosely during growth hormone therapy. The doses of antihyperglycaemic medicinal products mayrequire adjustment when growth hormone therapy is instituted in these patients.

Neoplasms

There is no evidence for increased risk of new primary cancers in patients treated with growthhormone.

In patients in complete remission from malignant diseases or who have been treated for benigntumours, growth hormone therapy has not been associated with an increased relapse rate.

Patients who have achieved complete remission of malignant diseases or who have been treated forbenign tumours should be followed closely for relapse after commencement of growth hormonetherapy. Growth hormone treatment should be interrupted in case of any development or reoccurrenceof malignant or benign tumour.

An overall slight increase in second neoplasms has been observed in childhood cancer survivorstreated with growth hormone, with the most frequent being intracranial tumours. The dominant riskfactor for secondary neoplasms seems to be prior exposure to radiation.

Benign intracranial hypertension

In the event of severe or recurrent headache, visual symptoms, nausea, and/or vomiting, a fundoscopyfor papilloedema is recommended. If papilloedema is confirmed, a diagnosis of benign intracranialhypertension should be considered and if appropriate the growth hormone treatment should bediscontinued. At present there is insufficient evidence to guide clinical decision making in patientswith resolved intracranial hypertension. If growth hormone treatment is restarted, careful monitoringfor symptoms of intracranial hypertension is necessary.

Thyroid function

Growth hormone increases the extrathyroidal conversion of T4 to T3 and may as such unmaskincipient hypothyroidism. As hypothyroidism interferes with the response to growth hormone therapy,patients should have their thyroid function tested regularly and should receive replacement therapywith thyroid hormone when indicated, see sections 4.5 and 4.8.

Use with oral oestrogen

Oral oestrogen influences the IGF-I response to growth hormone including somapacitan.

Female patients taking any form of oral oestrogen (hormone therapy or contraception) shouldconsider changing the route of oestrogen administration (e.g. transdermal-, vaginal hormone products)or use another form of contraception. If a woman on oral oestrogen is starting somapacitan therapy,higher starting doses and a longer titration period may be required (see section 4.2).

If a female patient taking somapacitan begins oral oestrogen therapy, the dose of somapacitan mayneed to be increased to maintain the serum IGF-I levels within the normal age-appropriate range.

Conversely, if a female patient on somapacitan discontinues oral oestrogen therapy, the dose ofsomapacitan may need to be reduced to avoid excess of somapacitan and/or undesirable effects, seesections 4.2 and 4.5.

When somapacitan is administered at the same site over a longer period of time, local changes in thesubcutaneous tissue such as lipohypertrophy, lipoatrophy, and acquired lipodystrophy might occur.

The injection site should be rotated to minimise the risk, see sections 4.2 and 4.8.

Antibodies

Antibodies to somapacitan were not observed in adult GHD patients. Few paediatric GHD patientstested positive for somapacitan binding antibodies. None of these antibodies were neutralising and noimpact on the clinical effects was observed. Testing for presence of anti-somapacitan antibodiesshould be carried out in patients who fail to respond to therapy.

Acute critical illness

The effect of growth hormone on recovery was studied in two placebo controlled trials involving522 critical ill adult patients suffering from complications following open heart surgery, abdominalsurgery, multiple accidental trauma or acute respiratory failure. Mortality was higher in patientstreated with 5.3 or 8 mg growth hormone daily compared to patients receiving placebo, 42% vs 19%.

Based on this information, these types of patients should not be treated with somapacitan. As there isno information available on the safety of growth hormone substitution therapy in acutely critical illpatients, the benefits of continued treatment in this situation should be weighed against the potentialrisks involved.

Growth hormone deficiency in adults is a lifelong disease and needs to be treated accordingly,however, experience in patients older than 60 years and in patients with more than five years oftreatment in adult growth hormone deficiency is still limited.

There have been few reports of pancreatitis during treatment with other growth hormone medicinalproducts. It should therefore be considered in somapacitan treated patients who develop unexplainedabdominal pain.

This medicinal product contains less than 1 mmol sodium (23 mg) per dose, i.e. it is essentiallysodium-free.

Cytochrome P450 metabolised drugs

Data from an interaction study performed in growth hormone deficient adults suggests that growthhormone administration may increase the clearance of compounds known to be metabolised bycytochrome P450 isoenzymes. The clearance of compounds metabolised by cytochrome P450 (e.g. sexsteroids, corticosteroids, anticonvulsants and cyclosporine) may be especially increased resulting inlower plasma levels of these compounds. The clinical significance of this is unknown.

Glucocorticoids

Growth hormone decreases the conversion of cortisone to cortisol and may unmask previouslyundiscovered central hypoadrenalism or render low glucocorticoid replacement doses ineffective, seesection 4.4.

Oral oestrogens

In females on oral oestrogen therapy, a higher dose of somapacitan may be required to achieve thetreatment goal, see sections 4.2 and 4.4.

Antihyperglycaemic products

Antihyperglycaemic treatment including insulin may require dose adjustment in case of somapacitanco-administration since somapacitan may decrease insulin sensitivity, see sections 4.4 and 4.8.

The metabolic effects of somapacitan can also be influenced by concomitant therapy with otherhormones, e.g. testosterone and thyroid hormones, see section 4.4.

There are no data from the use of somapacitan in pregnant women.

Studies in animal have shown reproductive toxicity, see section 5.3.

Sogroya is not recommended during pregnancy and in women of childbearing potential not usingcontraception.

It is unknown whether somapacitan/metabolites are excreted in human milk.

Available pharmacodynamic/toxicological data in animals have shown excretion of somapacitan inmilk, see section 5.3.

A risk to the breastfed newborns/infants cannot be excluded.

A decision must be made whether to discontinue breast-feeding or to discontinue/abstain from

Sogroya therapy taking into account the benefit of breast-feeding for the child and the benefit oftherapy for the woman.

There is no clinical experience with somapacitan use and its potential effect on fertility.

No adverse effects were observed on male and female fertility in rats,see section 5.3.

Sogroya has no or negligible influence on the ability to drive and use machines.

The commonly most frequently reported adverse drug reactions (ADRs) are (in decreasing order[paediatric GHD, adult GHD]) headache (12%, 12%), pain in extremity (9%, NA), hypothyroidism(5%, 2%), injection site reactions (5%, 1%), peripheral oedema (3%, 4%), arthralgia (2%, 7%),hyperglycaemia (2%, 1%), fatigue (2%, 6%) and adrenocortical insufficiency (1.5%, 3%).

The ADRs listed in Table 2 are based on the safety data from one ongoing pivotal phase 3 trial(52 weeks) in paediatric patients with GHD (baseline age: 2.5 to 11 years) and adverse reactions fromsomapacitan treatment. The frequencies of the ADRs have been calculated based on the frequencies inthe pivotal phase 3 trial.

The adverse reactions listed in Table 3 are based on the compiled safety data from three completedphase 3 trials in adult patients with GHD (baseline age: 19 to 77 years).

The ADRs are listed by MedDRA system organ class and frequency category defined as: Verycommon (≥ 1/10); common (≥1/100 to < 1/10); uncommon (≥ 1/1 000 to < 1/100); rare (≥ 1/10 000 to< 1/1 000); very rare (< 1/10 000).

Table 2: Adverse reactions from phase 3 clinical trial in paediatric GHD

MedDRA system organ class Very common Common

Endocrine disorders Hypothyroidism*

Adrenocorticalinsufficiency

Metabolism and nutrition Hyperglycaemiadisorders

Nervous system disorders Headache*

Musculo-skeletal and connective Arthralgiatissue disorders

Pain in extremity**

General disorders and Peripheral oedema*administration site conditions

Injection site reactions*#

*In general, these adverse reactions were non-serious, of mild severity and transient#The injection site reactions included injection site bruising (1.5%), injection site pain (1.5%),injection site haematoma (1.5%), and injection site swelling (0.8%).

**Primarily mild leg pain

Table 3: Adverse reactions from three completed phase 3 trials in adult patients with GHD

MedDRA Very common Common Uncommonsystem organclass

Endocrine Adrenocorticaldisorders insufficiency

Metabolism and Hyperglycaemia*nutrition disorders

Nervous system Headache Paraesthesia Carpal tunneldisorders syndrome

Skin and Rash* Lipohypertrophy*subcutaneous Urticaria* Pruritus*tissue disorders

Musculoskeletal Arthralgia Joint stiffnessand connective Myalgiatissue disorders Muscle stiffness*

General disorders Peripheral oedemaand Fatigueadministration Astheniasite conditions Injection sitereactions*

*In general, these adverse reactions were non-serious, mild or moderate severity and transient

Peripheral oedema

Peripheral oedema was commonly observed (3% in paediatric GHD and 4% in adult GHD). Growthhormone deficient patients are characterised by extracellular volume deficit. When treatment withgrowth hormone products is initiated, this deficit is corrected. Fluid retention with peripheral oedemamay occur. The symptoms are usually transient, dose dependent and may require transient dosereduction.

Adrenocortical insufficiency

Adrenocortical insufficiency was commonly observed (1.5% in paediatric GHD and 3% in adult

GHD), see section 4.4.

The safety of somapacitan has been established in children and adolescents aged 3 years and abovewith growth failure due to GHD. The safety profile of somapacitan in GHD patients under 3 years ofage is not established.

Reporting suspected adverse reactions after authorisation of the medicinal product is important. Itallows continued monitoring of the benefit/risk balance of the medicinal product. Healthcareprofessionals are asked to report any suspected adverse reactions via the national reporting systemlisted in Appendix V.

There is limited clinical experience with overdose of somapacitan.

Based on experience with daily growth hormone treatment, short term overdose with low bloodglucose levels initially, followed by high blood glucose levels can occur. These decreased glucoselevels have been detected biochemically, but without clinical signs of hypoglycaemia.

Long-term overdosage could result in signs and symptoms consistent with the known effects of humangrowth hormone excess.

Pharmacotherapeutic group: Pituitary and hypothalamic hormones and analogues, somatropin andsomatropin agonists, ATC code: H01AC07.

Somapacitan is a long-acting recombinant human growth hormone derivative. It consists of 191 aminoacids similar to endogenous human growth hormone, with a single substitution in the amino acidbackbone (L101C) to which an albumin binding moiety has been attached. The albumin bindingmoiety (side-chain) consists of a fatty acid moiety and a hydrophilic spacer attached to position 101 ofthe protein.

The mechanism of action of somapacitan is either directly via the GH-receptor and/or indirectly via

IGF-I produced in tissues throughout the body, but predominantly by the liver.

When growth hormone deficiency is treated with somapacitan a normalisation of body composition(i.e., decreased body fat mass, increased lean body mass) and of metabolic action is achieved.

Somapacitan stimulates skeletal growth in paediatric patients with GHD as a result of effects on thegrowth plates (epiphyses) of bones, see section 5.3.

IGF-I

IGF-I is a generally accepted biomarker for efficacy in GHD.

A dose-dependent IGF-I response is induced following somapacitan administration.

A steady state pattern in IGF-I responses is reached after 1-2 weekly doses.

The IGF-I levels fluctuate during the week. The IGF-I response is maximal after 2 to 4 days.

Compared with daily GH treatment, the IGF-I profile of somapacitan differs, see Figure 1.

In paediatric GHD patients somapacitan produces a dose linear IGF-I response, with a change of0.02 mg/kg on average resulting in a change in IGF-I standard deviation score (SDS) of 0.32.

somapacitansomatropin

Days at steady state

Figure 1: Model-derived IGF-I profiles during steady state of somapacitan and somatropin(based on data from adult GHD)

Paediatric GHD

REAL 4 (phase 3)

The efficacy and safety of once weekly somapacitan was evaluated in a 52 weeks randomised, multi-center, open-label, active-controlled, parallel-group phase 3 trial (REAL 4) in 200 treatment-naïve,paediatric patients with GHD. Patients were randomised to 0.16 mg/kg/week once weeklysomapacitan (N=132) or 0.034 mg/kg/day once daily somatropin (N=68).

At baseline, the 200 patients had a mean age of 6.4 years (range: 2.5 to 11 years). 74.5% of thepatients were male.

The annualised height velocity at week 52 was similar for somapacitan and somatropin (Table 4).

Table 4: Growth results at week 52 in paediatric patients with GHD

Once-weekly Once-daily Estimate of treatment differencesomapacitan somatropin (95% CI) (somapacitan minus(N=132) (N=68) somatropin)

Annualised height 11.2 11.7 -0.5 [-1.1; 0.2]velocity (cm/year)

In accordance with this, changes at week 52 compared to baseline with respect to the height SDS and

IGF-I SDS were also similar for somapacitan and somatropin (Table 5).

T able 5: Height SDS and IGF-I SDS in paediatric patients with GHD - 52 weeks treatment

Once-weekly Once-daily somatropin Estimate of treatmentsomapacitan (N=68) difference (95% CI)(N=132) (somapacitan minussomatropin)

Height SDS, baselinea -2.99 -3.47

Height SDS, change from 1.25 1.30 -0.05 [-0.18; 0.08]baseline

IGF-I SDS, baselinea -2.03 -2.33

IGF-I SDS, week 52a 0.28 0.10

IGF-I SDS level change 2.36 2.33 0.03 [-0.30; 0.36]from baselinea Observed mean

The vast majority of paediatric patients (96.9%) in the trial achieved an average IGF-I SDS levelwithin normal range (-2 to +2) after 52 weeks of treatment with once weekly somapacitan (Table 6). Alow number of patients had average IGF-I SDS above +2 (2.3%) and no patients had average IGF-I

SDS above +3.

Table 6: Average IGF-I SDS values after 52 weeks of treatment of paediatric patients with GHDwith once weekly somapacitan

IGF-I SDS category Week 52 average(N=132)<-2 0.8%

- 2 to 0 21.2%0 to +2 75.8%+2 to +3 2.3%>+3 0

REAL 3 (phase 2)

A total of 59 GH treatment-naïve GH-deficient paediatric patients completed a 26-week main periodand a 26-week extension in a 4-arm parallel group trial with once weekly somapacitan at dose levelsof 0.04, 0.08 and 0.16 mg/kg/week and active control arm of 0.034 mg/kg/day daily somatropin. Thepatients continued in a 104-week open-label safety extension parallel arms with somapacitan0.16 mg/kg/week and daily somatropin 0.034 mg/kg/day. All patients were afterwards transferred toonce weekly somapacitan 0.16 mg/kg/week in a 208-week long-term safety extension.

Treatment with once weekly somapcitan led to continuous treatment benefits up to at least week 208.

Height SDS was -1.06 (change from baseline: 2.85) in 38 patients.

Height outcome obtained at week 208 in patients switching from 0.034 mg/kg/day daily somatropin to0.16 mg/kg/week once weekly somapacitan at week 156 indicated that treatment benefits with daily

GH treatment are maintained after switching to once weekly somapacitan.

Mean IGF-I SDS remained within the normal range for all groups.

Adult GHD

In a 34-week placebo-controlled (double-blind) and active-controlled (open) trial, 301 treatment-naïveadult patients with GHD were randomised (2:1:2) and 300 were exposed to once-weekly somapacitanor to placebo or to daily somatropin for a 34-week treatment period (main phase of the trial). Thepatient population had a mean age of 45.1 years (range 23-77 years; 41 patients were 65 years orabove), 51.7% were females, and 69.7% had adult onset GHD.

A total of 272 adult GHD patients who completed the 34-week main phase continued in a 53-weekopen-label extension period. Subjects on placebo were switched to somapacitan and patients onsomatropin were re-randomised (1:1) to either somapacitan or somatropin.

Observed clinical effects for the main endpoints in the main treatment phase (Table 7) and extensiontreatment phase (Table 8) are presented below.

Table 7: Results at 34 weeks

Difference Differencesomapacitan-

Change from baseline somapacitan -at 34 weeksa somapacitan somatropin placebo placebo somatropin[95% CI] [95% CI]p-value

Number of subjects (N) 120 119 61

Truncal fat % -1.53 1.17 [0.23;(Primary endpoint) -1.06 -2.23 0.47 [-2.68; -0.38] 2.11]0.0090b

- 14 -1

Visceral adipose tissue(cm2) -10 -9 3 [-21; -7] [-7; 4]679 96

Appendicular skeletalmuscle mass (g) 558 462 -121 [340; 1,019] [-182; 374]1144 49

Lean body mass (g) 1,394 1,345 250 [459; 1,829] [-513; 610]2.40 0.02

IGF-I SDS level 2.40 2.37 -0.01 [2.09; 2.72] [-0.23; 0.28]

Abbreviations: N = Number of subjects in full analysis set, CI = Confidence interval, DM=Diabetes mellitus.

IGF-I SDS: Insulin-like growth factor-I standard deviation score.a Body composition parameters are based on dual-energy X-ray absorptiometry (DXA) scanning.b The primary analysis was a comparison of changes from baseline for somapacitan and placebo in truncal fat %.

Changes in truncal fat % from baseline to the 34 week’s measurements was analysed using an analysis ofcovariance model with treatment, GHD onset type, sex, region, DM and sex by region by DM interaction asfactors and baseline as a covariate incorporating a multiple imputation technique where missing week 34 valueswere imputed based on data from the placebo group.

Post-hoc subgroup analysis of changes from baseline in truncal fat percentage (%) compared toplacebo at week 34 showed an estimated treatment difference (somapacitan-placebo) of -2.49% [-4.19;

- 0.79] in men, -0.80% [-2.99; 1.39] in women not on oral oestrogen, -1.44% [-3.97; 1.09] in women onoral oestrogen.

Table 8: Results at 87 weeks

Difference

Change from somapacitan/baseline at 87 somapacitan/ somatropin/ placebo/ somatropin/ somapacitan vsweeksa somapacitan somatropin somapacitan somapacitan somatropin/somatropin[95% CI]

Number ofsubjects (N) 114 52 54 511.15

Truncal fat % -1.52 -2.67 -2.28 -1.35 [-0.10; 2.40]0.22

Visceral adiposetissue (cm2) -6.64 -6.85 -10.21 -8.77 [-10; 10]

Appendicular 97.02skeletal muscle 546.11 449.09 411.05 575.80 [-362; 556]mass (g)433.32

Lean body mass(g) 1,739.05 1,305.73 1,660.56 1,707.82 [-404; 1271]a Body composition parameters are based on DXA scanning.

Observed and simulated IGF-I SDS levels in the clinical study

In the main phase of the clinical study IGF-I SDS values of 0 and above were overall achieved in 53%of somapacitan-treated adult GHD study patients after an 8-week dose titration period. This proportionwas however lower in particular subgroups such as women on oral oestrogen (32%) and patients withchildhood-onset (39%) (Table 9). Post-hoc simulation analyses indicated that the proportions of adult

GHD patients achieving IGF-I SDS levels above 0 are expected to be higher in case somapacitan dosetitration beyond 8 weeks would be allowed. In this simulation analysis, it was assumed thatsomapacitan dose titration was well-tolerated in all patients until the IGF-I SDS target range or asomapacitan dose of 8 mg per week would be achieved.

Table 9: Proportions of somapacitan-treated adult GHD patients with IGF-I SDS levels above 0

Women not Women on Childhood- Adult-

Subgroups Men on oral oral onset adult onset Alloestrogen oestrogen GHD adult

GHD

Observeda 71% 46% 32% 39% 60% 53%

Post-hocsimulations 100% 96% 70% 84% 92% 90%a The trial was designed to titrate towards a IGF-I SDS level above -0.5

Maintenance dose varies from person to person and between male and female patients. The averagesomapacitan maintenance dose observed in the phase 3 clinical trials was 2.4 mg/week.

Paediatric and adult GHD

The safety profile of somapacitan was similar to the well-known safety profile of somatropin. No newsafety issues were identified,see section 4.8.

Anti-drug antibodies (ADA) were uncommonly detected in peadiatric patients (16/132). None of theseantibodies were neutralising. No evidence of ADA impact on pharmacokinetics, efficacy or safety wasobserved. No anti-drug antibodies were detected in adult patients.

The European Medicines Agency has waived the obligation to submit the results of studies with

Sogroya in all subsets of the paediatric population in growth hormone deficiency (see section 4.2 forinformation on paediatric use).

Somapacitan has pharmacokinetic properties compatible with once weekly administration. Thereversible binding to endogenous albumin delays elimination of somapacitan and thereby prolongs thein vivo half-life and duration of action.

The pharmacokinetics of somapacitan following subcutaneous administration have been investigatedat dose levels from 0.02 to 0.16 mg/kg/week in paediatric population (2.5 to 14 years), at dose levelsfrom 0.01 to 0.32 mg/kg in healthy adults, and in doses up to 0.12 mg/kg in patients with adult GHD.

Overall, somapacitan displays non-linear pharmacokinetics across the investigated dose range.

However, in the clinically relevant dose range of somapacitan in adult GHD, somapacitanpharmacokinetics are approximately linear.

In paediatric GHD, a somapacitan dose of 0.16 mg/kg/week corresponds to an average concentrationof 80.2 ng/mL and in adult GHD, somapacitan doses in the clinically relevant range correspond toaverage concentrations of 0.1-36.2 ng/mL.

In adult and paediatric patients with GHD median tmax ranged from 4 to 25.5 hours at doses from0.02 mg/kg/week to 0.16 mg/kg/week.

Steady state exposure was achieved following 1-2 weekly administration.

Absolute bioavailability of somapacitan in humans has not been investigated.

Somapacitan is extensively bound (>99%) to plasma proteins and is expected to be distributed likealbumin. Based on population PK analyses, the estimated volume of distribution (V/F) was 1.7 L inpaediatric GHD patients and 14.6 L in adult GHD patients.

Following a single dose and repeated dosing of 0.16 mg/kg/week the terminal half-life wasapproximately 34 hours in paediatric GHD patients.

The terminal half-life was estimated with geometric means ranging from approximately 2 to 3 days atsteady state in paediatric and adult GHD patients (doses: 0.02 to 0.12 mg/kg).

Somapacitan will be present in circulation for approximately 2 weeks after the last dose. Little to noaccumulation (mean accumulation ratio: 1-2) of somapacitan following multiple dosing has beenobserved.

Somapacitan is extensively metabolised by proteolytic degradation and cleavage of the linkersequence between the peptide and albumin binder.

Somapacitan was extensively metabolised before excretion and no intact somapacitan was foundneither in urine, which was the main excretion route (81%), nor in faeces where 13% of somapacitanrelated material was found, indicating full biotransformation before excretion.

Paediatric GHD patients

Based on population pharmacokinetic analysis gender, race and body weight do not have a clinicallymeaningful effect on the pharmacokinetics following weight-based dosing.

Adult GHD patients

Subjects older than 60 years have higher exposure (29%) than younger subjects at the samesomapacitan dose. A lower starting dose for subjects above 60 years is described in section 4.2.

Female subjects and in particular female subjects on oral oestrogen, have lower exposure (53% forfemales on oral oestrogen and 30 % for females not on oral oestrogen) than male subjects at the samesomapacitan dose. A higher starting dose for females on oral oestrogen is described in section 4.2.

There was no difference in somapacitan exposure and IGF-I response between Japanese and Whitesubjects. Despite a higher exposure in Asian Non-Japanese compared to White at the samesomapacitan dose, White, Japanese and Asian Non-Japanese needed the same doses to reach similar

IGF-I levels. Therefore, there is no dose adjustment recommendation based on race.

Ethnicity (Hispanic or Latino 4.5% (15 subjects received somapacitan)) was not investigated due tosmall sample size in the development programme.

Despite a higher exposure in subjects with low body weight as compared to subjects with high bodyweight at the same somapacitan dose, subjects needed the same doses to reach similar IGF-I levelsacross the body weight range 35 kg to 150 kg. Therefore, there is no dose adjustment recommendationbased on body weight.

A somapacitan dose of 0.08 mg/kg at steady state resulted in higher exposures in subjects with renalimpairment, most pronounced in subjects with severe renal impairment and in subjects requiringhaemodialysis, where AUC 0-168h ratios to normal renal function were 1.75 and 1.63, respectively. Ingeneral, somapacitan exposure tended to increase with decreasing GFR.

Higher IGF-I AUC0-168h levels were observed in subjects with moderate and severe renal impairment andsubjects requiring haemodialysis, with ratios to normal renal function of 1.35, 1.40 and 1.24respectively.

Due to the modest increase observed in IGF-I combined with the low recommended starting doses andthe individual dose titration of somapacitan, there is no dose adjustment recommendation in patientswith renal impairment.

A somapacitan dose of 0.08 mg/kg at steady state resulted in higher exposure in subjects withmoderate hepatic impairment with ratios to normal hepatic function of 4.69 for AUC0-168h and 3.52 for

Cmax.

Lower somapacitan stimulated IGF-I levels were observed in subjects with mild and moderate hepaticimpairment compared to subjects with normal hepatic function (ratio to normal was 0.85 for mild and0.75 for moderate).

Due to the modest decrease observed in IGF-I combined with the individual dose titration ofsomapacitan, there is no dose adjustment recommendation in patients with hepatic impairment.

Preclinical data reveal no special hazard for humans based on conventional studies of safetypharmacology, repeat-dose toxicity, genotoxicity or pre- and postnatal development.

No carcinogenicity studies have been performed with somapacitan.

No adverse effects were observed on male and female fertility in rats at a dose resulting in exposure atleast 13 and 15-times greater than the expected maximum clinical exposure at 8 mg/week for malesand females, respectively. However, irregular female oestrus cycle was seen at all doses treated.

No evidence of foetal harm was identified when pregnant rats and rabbits were administeredsubcutaneous somapacitan during organogenesis at doses leading to exposures well above expectedexposure at the maximum clinical dose of 8 mg/week (at least 18-fold). At high doses leading toexposure at least 130-fold above the expected maximum clinical exposure at 8 mg/week,short/bent/thickened long bones were found in pups from female rats receiving somapacitan. Suchfindings in rats are known to resolve after birth and should be regarded as minor malformations, notpermanent abnormalities.

Foetal growth was reduced when pregnant rabbits were dosed with somapacitan subcutaneously atexposures at least 9-fold above the expected exposure at the maximum clinical dose of 8 mg/week.

In lactating rats, somapacitan related material was secreted into milk but to a lower level thanobserved in plasma (up to 50% of level in plasma).

Histidine

Mannitol

Poloxamer 188

Phenol

Water for injections

Hydrochloric acid (for pH adjustment)

Sodium hydroxide (for pH adjustment).

In the absence of compatibility studies, this medicinal product must not be mixed with other medicinalproducts.

2 years.

After first opening6 weeks. Store in a refrigerator (2°C - 8°C).

Do not freeze. Keep away from the freezing element.

Keep Sogroya in the outer carton with the pen cap on to protect from light.

Before and after first opening

If refrigeration is not possible (e.g. during travelling), Sogroya may be kept temporarily attemperatures up to 30°C for up to a total of 72 hours (3 days). Return Sogroya to the refrigerator againafter storage at this temperature. If stored out of refrigeration and then returned to refrigeration, thetotal combined time out of refrigeration should not exceed 3 days, monitor this carefully. The Sogroyapen should be discarded, if it has been kept up to 30°C for more than 72 hours (3 days) or for anyperiod of time kept above 30°C.

Store in a refrigerator (2°C - 8°C). Do not freeze. Keep away from the freezing element.

Keep Sogroya in the outer carton with the pen cap on to protect from light.

For storage conditions after first opening of the medicinal product, see section 6.3.

The pre-filled pen consists of 1.5 mL solution in a glass cartridge (Type I colourless glass) with aplunger made of chlorobutyl rubber and a stopper made of bromobutyl/isoprene rubber sealed with analuminium cap. The cartridge is contained in a multidose disposable pen made of polypropylene,polyacetal, polycarbonate and acrylonitrile butadiene styrene and in addition two metal springs. Thecartridge is permanently sealed in a pre-filled pen.

Sogroya 5 mg/1.5 mL solution for injection in pre-filled pen

A colour-coded pre-filled pen with the dose button on the pen coloured teal.

Sogroya 10 mg/1.5 mL solution for injection in pre-filled pen

A colour-coded pre-filled pen with the dose button on the pen coloured yellow.

Sogroya 15 mg/1.5 mL solution for injection in pre-filled pen

A colour-coded pre-filled pen with the dose button on the pen coloured rubine red.

Pack sizes of 1 pre-filled pen and multipack of 5 (5 packs of 1) pre-filled pens. Not all pack sizes maybe marketed.

The pen is for use by one person only.

Sogroya should not be used if the solution does not appear clear to slightly opalescent, colourless toslightly yellow and free from visible particles.

Sogroya must not be used if it has been frozen.

The cartridge must not be taken out of the pre-filled pen and refilled.

A needle must always be attached before use. Needles must not be re-used. The injection needleshould be removed after each injection and the pen should be stored without a needle attached. Thismay prevent blocked needles, contamination, infection, leakage of solution and inaccurate dosing.

In the event of blocked needles, patients must follow the instructions described in the instructions foruse accompanying the package leaflet.

Needles are not included. Sogroya pre-filled pen is designed to be used with disposable needles of alength between 4 mm and 8 mm and a gauge between 30G and 32G.

Any unused medicinal product or waste material should be disposed of in accordance with localrequirements.

Novo Nordisk A/S

Novo Allé

DK-2880 Bagsværd

Denmark

EU/1/20/1501/001

EU/1/20/1501/002

EU/1/20/1501/003

EU/1/20/1501/004

EU/1/20/1501/005

EU/1/20/1501/006

Date of first authorisation: 31 March 2021

Detailed information on this medicinal product is available on the website of the European Medicines

Agency http://www.ema.europa.eu.